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Summary
RAF kinase inhibitors can induce ERK cascade signaling by
promoting dimerization of RAF family members in the pres-
ence of oncogenic or normally activated RAS [1–3]. This
interaction is mediated by a dimer interface region in the
RAF kinase domain that is conserved in members of the
ERK cascade scaffold family, kinase suppressor of RAS
(KSR) [4, 5]. In this study, we find that most RAF inhibitors
also induce the binding of KSR1 to wild-type and oncogenic
B-RAF proteins, including V600E B-RAF, but promote little
complex formation between KSR1 and C-RAF. The inhib-
itor-induced KSR1/B-RAF interaction requires direct binding
of the drug to B-RAF and is dependent on conserved dimer
interface residues in each protein, but, unexpectedly, is
not dependent on binding of B-RAF to activated RAS. Inhib-
itor-induced KSR/B-RAF complex formation can occur in
the cytosol and is observed in normal mouse fibroblasts,
as well as a variety of human cancer cell lines. Strikingly,
we find that KSR1 competes with C-RAF for inhibitor-
induced binding to B-RAF and, as a result, alters the effect
of the inhibitors on ERK cascade signaling.
Results and Discussion
RAF Inhibitors Induce KSR1/B-RAF Binding
Adenosine triphosphate (ATP)-competitive RAF inhibitors can
promote dimerization of the RAF kinases in the presence of
oncogenic or activated wild-type (WT) RAS [1–3]. Because
the KSR1 scaffold also interacts with RAF in response to
RAS activation [6, 7] and contains residues homologous to
those in the RAF dimer interface region [4, 5] that are critical
for inhibitor-induced RAF dimerization [1], we examined
whether the RAF inhibitors might also promote KSR1/RAF
binding. KSR2/2 mouse embryonic fibroblasts (MEFs) [8] that
stably express Pyo-tagged WT-KSR1 (WT-KSR1 MEFs) were
treated with the RAF inhibitors PLX4720, Sorafenib, L779450,
or SB590885 for 1 hr, after which complex formation between
KSR1 and the endogenous RAF proteins was examined. As
shown in Figure 1A, Sorafenib, L779450, and SB590885 all
induced robust association of KSR1 with B-RAF but little or
no interaction with C-RAF. Inhibitor-induced KSR1/B-RAF
binding was dose dependent, increasing with greater drug
concentration (see Figure S1A available online). Notably,
PLX4720 did not promote binding of KSR1 to either RAF
protein. Further investigation revealed that only when C-RAF
was highly overexpressed (w25-fold above endogenous
levels) could some interaction between KSR1 and C-RAF be*Correspondence: morrisod@mail.nih.govdetected following L779450 treatment; however, even with
high C-RAF overexpression, binding was still not observed in
PLX4720-treated cells (Figure S1B). Unlike the other inhibitors
tested, PLX4720 binding causes a shift in the B-RAF a-helix
[1, 9], which may perturb the KSR1/B-RAF interaction and
account for the absence of KSR1/B-RAF complexes in
PLX4720-treated cells.
Because the RAF inhibitors are normally used in the context
of oncogenic signaling, a panel of melanoma and nonsmall cell
lung carcinoma lines were screened for KSR1 expression, and
four representative lines were evaluated that possessed
detectable KSR1 levels and oncogenic mutations in either
RAF or RAS (Figure S1C). In these experiments, treatment
with L779450, but not PLX4720, induced strong KSR1/B-RAF
binding in A549 and HMCB cells that possess oncogenic
RAS proteins, in the Cal12T line that contains an impaired
activity B-RAF mutant, and, surprisingly, in A375 melanoma
cells that are homozygous for V600E-B-RAF (Figure 1B; Fig-
ure S1D). This later finding is in contrast to RAF inhibitor-
induced C-RAF/B-RAF dimerization, which involves binding
of C-RAF to WT B-RAF or impaired activity B-RAF mutants,
but not to the high activity V600E-B-RAF (Figure S1D) [1–3].
Of note, little or no inhibitor-induced binding between KSR1
and C-RAF was observed in these lines (Figure 1B).
To further evaluate the ability of oncogenic B-RAF proteins
to interact with KSR1 upon inhibitor treatment, we treated
WT-KSR1 MEFs stably expressing Flag-tagged V600E (high
activity)-, G466A (moderate activity)-, or D594G (impaired
activity)-B-RAF [10] with L779450 and monitored the binding
of KSR1 to the Flag-B-RAF proteins. As shown in Figure 1C,
basal association of KSR1 was higher for the moderate and
impaired activity B-RAF mutants; however, inhibitor-induced
binding was equivalent for V600E, G466A, and D594G-B-RAF
(Figure 1C), indicating that the activity level of B-RAF has no
impact on the drug-mediated interaction with KSR1.
Inhibitor-Induced KSR1/B-RAF Complex Formation
Requires Binding of the Inhibitor to B-RAF and an Intact
B-RAF Dimer Interface but Is Not RAS-Dependent
To investigate the requirements in B-RAF for inhibitor-induced
binding to KSR1, we treated WT-KSR1 MEFs stably express-
ing various Flag-tagged B-RAF proteins with L779450 and
examined KSR1/B-RAF binding. In coimmunoprecipitation
assays, the T529M-B-RAF gatekeeper mutant [11] failed to
interact with KSR1 (Figure 1D), demonstrating that as with
inhibitor-induced C-RAF/B-RAF dimerization [1–3], drug-
mediated KSR1/B-RAF complex formation requires direct
binding of the inhibitor to B-RAF.Mutation of a conserved argi-
nine residue (R509H) in the B-RAF dimer interface region [5]
also disrupted the interaction between KSR1 and B-RAF
(Figure 1E), consistent with previous reports that an intact
B-RAF dimer interface is required for inhibitor-induced
C-RAF/B-RAF dimerization [1] and for growth factor-mediated
KSR1/B-RAF binding (Figure 1E) [5]. However, S729A-B-RAF,
which contains a mutation in the C-terminal 14-3-3 binding
site, was competent to bind KSR1 in response to either
L779450 or EGF treatment (Figure 1E). Surprisingly, mutation
of the RAS binding site in B-RAF (R188; [12]) had no effect on
Figure 1. RAF Inhibitors Induce KSR1/B-RAF Binding
(A) CyclingWT-KSR1 MEFs were treated with the indicated drugs (10 mM for 1 hr). Pyo-KSR1 or endogenous B-RAF or C-RAF complexes were isolated and
examined by immunoblot analysis as indicated.
(B) A549, Cal12T, A375, and HMCB cancer lines were treatedwith L779450 or PLX7420 (10 mM for 1 hr). Endogenous KSR1 complexes were examined for the
presence of endogenous B-RAF or C-RAF.
(C–F) Cycling WT-KSR1 MEFs stably expressing the indicated Flag-B-RAF proteins were treated with L779450 (L, 10 mM for 1 hr), after which Pyo-KSR1/
Flag-B-RAF binding was assessed. In parallel experiments (E and F), Pyo-KSR1 complexes were isolated from serum-starved cells treated with EGF
(100 ng/ml for 5 min). Of note, RAF inhibitor-induced KSR1/B-RAF binding was increased in comparison to EGF-mediated binding and required shorter
exposure times for detection. Protein expression levels are also shown.
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564L779450-induced KSR1/B-RAF binding (Figure 1F). Thus, in
contrast to both inhibitor-induced C-RAF/B-RAF dimerization
[2] and EGF-mediated KSR1/B-RAF binding (Figure 1F), the
inhibitor-induced KSR1/B-RAF interaction is not RAS-depen-
dent (requirements summarized in Table S1).
All KSR Proteins Competent to Bind B-RAF
Can Form Inhibitor-Induced Complexes
To investigate the requirements in KSR for inhibitor-induced
binding to B-RAF, we treated KSR2/2MEFs stably expressing
various Pyo-tagged WT and mutant KSR proteins with
L779450 and analyzed them for KSR/B-RAF complex forma-
tion. As shown in Figure 2A, the mammalian KSR proteins
KSR1 [4], KSR2 [13], and B-KSR1 (a brain-specific splice
variant of KSR1 [14]) were all competent to bind B-RAF
in response to L779540 treatment. Interestingly, inhibitor
treatment promoted little KSR1/KSR2 heterodimerization(Figure S2A) and no detectable KSR1/KSR1 homodimerization
(Figure S2B) in MEFs. Further evidence that the RAF inhibitors
may bind only weakly to the KSR proteins, mutation of the pre-
dicted gatekeeper site in KSR1 (T636M) reduced, but did not
eliminate, complex formation with B-RAF in L779450-treated
cells (Figure S2C). In contrast, mutation of the conserved
arginine residue in the KSR1 dimer interface (R615H) [5]
abolished B-RAF binding following L779450 treatment, as
well as EGF stimulation (Figure 2B). Inhibitor-induced KSR1/
B-RAF complex formation was also perturbed by the C809Y
mutation (Figure 2B), which disrupts the KSR1/MEK interac-
tion [14, 15] and growth factor-mediated KSR1/B-RAF binding
[7]. However, S297A/S392A-KSR1, amutant that is defective in
14-3-3 binding [16] and exhibits enhanced growth factor-
mediated binding to B-RAF (Figure 2B), demonstrated an
increased interaction with B-RAF after L779450 treatment
(Figure 2B).
Figure 2. Requirements in KSR1 for Inhibitor-Induced
B-RAF/KSR1 Binding
(A–C) Cycling KSR2/2 MEFs expressing the indicated
KSR proteins were treated with L779450 (L, 10 mM for
1 hr), after which Pyo-KSR/B-RAFbindingwas assessed.
In parallel experiments (B and C), Pyo-KSR1 complexes
were isolated from serum-starved cells treated with
EGF (100 ng/ml for 5 min).
(D) Cycling KSR2/2 and WT-KSR1 MEFs were treated
with L779450 (10 mM for 1 hr) prior to cell fractionation.
Membrane and cytosolic fractions were examined for
KSR1/B-RAF complex formation and for Pyo-KSR1,
B-RAF, and C-RAF levels.
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C-terminal region of KSR1 (C0-KSR1, amino acids 530–873)
formed complexes with B-RAF in L779450-treated cells (Fig-
ure 2C), despite the fact that this mutant lacks the N-terminal,
membrane-targeting C1 domain [17] and cannot localize to the
plasma membrane or interact with B-RAF after EGF treatment
(Figure 2C) [7]. This finding together with the observation that
binding of B-RAF to KSR1 in response to L779450 treatment is
RAS-independent indicates that the inhibitor-induced KSR1/
B-RAF interaction can occur in the cytosol. In further support
of this conclusion, a KSR1 protein containing mutations that
disrupt the structure of the membrane-targeting C1 domain
(C1m-KSR1; [17]) also formed inhibitor-induced complexes
with B-RAF (Figure S2C) and KSR1/B-RAF complexes were
abundantly detected in the cytosolic compartment of WT-
KSR1 MEFs that were fractionated after inhibitor treatment
(Figure 2D).
KSR1 Competes with C-RAF for Inhibitor-Induced Binding
to B-RAF
The finding that inhibitor-induced complex formation between
KSR1/B-RAF can occur in the cytosol raises the interesting
possibility that KSR1 might compete with C-RAF for inhibitor-
induced binding to B-RAF, which has been shown to be RAS-
dependent and occur at the plasmamembrane [1, 2]. To begin
to investigate this possibility, we treated KSR2/2 MEFs and
those expressing WT-KSR1 or various KSR1 mutants with
L779450 and monitored the complex formation between the
endogenous C-RAF/B-RAF proteins and the binding of KSR1
to endogenous B-RAF. As shown in Figure 3A, L779450
strongly induced C-RAF/B-RAF dimerization in KSR2/2
MEFs; however, this interaction was significantly reduced in
WT-KSR1 MEFs, where induction of KSR1/B-RAF binding
was observed. L779450-induced B-RAF/C-RAF dimerization
was not reduced in MEFs expressing the R615H- and C809Y-
KSR1 mutants unable to bind B-RAF, whereas B-RAF/C-RAF
dimerization was abolished in cells expressing S297A/S392A-
KSR1 that exhibits enhanced inhibitor-induced B-RAF binding
(Figure 3A). The presence of WT-KSR1 also reduced complex
formation between C-RAF and the oncogenic G466A- and
D594G-B-RAF proteins in L779450-treated cells (Figure S3).
Moreover, in cell fractionation experiments, B-RAF and
C-RAF were strongly recruited into the membrane fraction of
L779450-treated KSR2/2 MEFs, whereas in L779450-treatedWT-KSR1 MEFs that contain high levels of
cytosolic KSR1/B-RAF complexes, little to no
membrane recruitment was observed (Fig-
ure 2D). In further support that KSR1 can
compete with C-RAF for inhibitor-inducedbinding toB-RAF,C-RAF/B-RAFdimerizationwasconsistently
reduced in WT-KSR1 MEFs versus KSR2/2 MEFs when cells
were treated with any of the RAF inhibitors capable of
promoting KSR1/B-RAF binding (Figures 3B and 3C), and
C-RAF/B-RAF dimerization was still reduced in L779450-
treated WT-KSR1 MEFs even when RASV12 was expressed
(Figure 3C). In contrast, equivalent C-RAF/B-RAF dimerization
was observed in KSR2/2 and WT-KSR1 MEFs treated with
PLX4720, which does not promote KSR1/B-RAF binding, and
PLX4720-induced C-RAF/B-RAF dimerization was signifi-
cantly increased in both cells lines when RASV12 was ex-
pressed (Figure 3C).
KSR1 Can Alter the Effect of RAF Inhibitors on ERK
Cascade Signaling
Given the above results that KSR1 can competewith C-RAF for
inhibitor-induced binding to B-RAF, we next examined the
effect of KSR1 on inhibitor-induced ERK cascade signaling.
Strikingly, we found that activated pERK levels differed signif-
icantly in KSR2/2 versus WT-KSR1 MEFs when treated with
inhibitors that promote KSR/B-RAF binding. As shown in Fig-
ure 3B, although basal ERK activation was higher in WT-KSR1
MEFs, pERK levels were either unchanged (SB590885) or
inhibited in WT-KSR1 cells (L779450 and Sorafenib) treated
with inhibitors that promote KSR1/B-RAF binding. Conversely,
these inhibitors all stimulated ERK activation in KSR2/2MEFs,
with SB590885 inducing significantly higher pERK levels than
seen in untreated or SB590885-treated WT-KSR1 MEFs (Fig-
ure 3B). Oncogenic RASV12 increased the basal pERK levels
in both KSR2/2 and WT-KSR1 MEF; however, treatment with
L779450 was still able to suppress ERK activation in cells
expressing KSR1, but had no inhibitory effect in KSR2/2 cells
(Figure 3C). Interestingly, pERK levels were equivalent and not
suppressed in both KSR2/2 and WT-KSR1 MEFs treated with
PLX4720, which does not promote KSR1/B-RAF binding.
When RAF catalytic activity was monitored (Figure 4A), we
observed a slight change in B-RAF activity in L779450-treated
KSR2/2MEFs (1.2-fold to 1.5-fold), but no change inWT-KSR1
MEFs. Notably, C-RAF activity increased w25-fold with 1 mM
L779450 treatment in KSR2/2 cells but only 2-fold to 3-fold in
WT-KSR1 MEFs. Moreover, 10 mM L799450 still activated
C-RAF 8-fold to 10-fold in KSR2/2 MEFs, but inhibited RAF
activity in WT-KSR1 cells (Figure 4A). ERK activation in the
KSR2/2 and WT-KSR1 MEFs was also found to correlate
Figure 3. KSR1 Competes with C-RAF for Inhibitor-Induced Binding to B-RAF
(A–C) Cycling KSR2/2MEFs and those expressing the indicated KSR1 proteins were treated with L779450 (L), SB590885 (SB), Sorafenib (Soraf), or PLX4720
(P) (10 mM for 1 hr). Pyo-KSR1 or endogenous C-RAF complexes were isolated and examined for endogenous B-RAF. Lysates were analyzed for pERK and
tubulin (loading control) levels. Cells stably expressing RASV12 were also examined in (C).
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ure 4A). As expected, the presence of KSR1 had no effect on
either B-RAF or C-RAF activity in cells treated with PLX4720
(Figure S4).
To determinewhether KSR1 can influence the effect of inhib-
itor treatment in cancer cell lines, we used a lentivirus express-
ing a shKSR1 RNA to generate A549, HMCB, and A375 lines
depleted of KSR1 (Figure 4B). ERK activation was then
compared in these and the vector control lines after drug treat-
ment. Consistent with studies showing that L779450 and
SB590885 can effectively inhibit V600E-B-RAF activity [2, 3],
depletion of KSR1 had no effect on the ability of these drugs
to block ERK activation in A375 cells homozygous for V600E-
B-RAF. As previously reported [3], high inhibitor treatment
also blocked ERK activation in the HMCB and A549 lines that
contain oncogenic RAS proteins (Figure 4B). However, treat-
ment with lower doses (1 mM) of L779450 or SB590885
promoted ERK activation in the HMCB and A549 lines, and
pERK levels were increased 2-fold to 5-fold in cells depleted
of KSR1.
Conclusions
Determining effective therapeutic strategies for treating
human cancer is a significant challenge for the scientific and
medical communities. Recent studies have shown that treat-
ment with RAF kinase inhibitors can paradoxically induce
ERK cascade signaling by promoting dimerization of RAF
family members in the presence of activated RAS. Our findings
reveal that select RAF inhibitors can also promote KSR1/
B-RAF binding. Like inhibitor-induced C-RAF/B-RAF dimer-
ization, drug-induced KSR1/B-RAF binding requires an intact
KSR1/B-RAF dimer interface and binding of the inhibitor to
the ATP binding pocket of B-RAF. However, drug-mediated
KSR1/B-RAF complex formation differs from inhibitor-inducedC-RAF/B-RAF dimerization and normal growth factor-medi-
ated KSR1/B-RAF binding in that it is RAS-independent and
can occur in the cytoplasm. Strikingly, and as a result of this
difference, we find that KSR1 competes with C-RAF for inhib-
itor-induced binding to B-RAF (Figure 4C) and attenuates
the activating effect of the inhibitors on ERK cascade
signaling. Together, these findings suggest that KSR1 expres-
sion levels may impact the therapeutic effect of select RAF
inhibitors.
Experimental Procedures
DNA Constructs and Generation of Stable Cell Lines
pBabe retroviral constructs encoding Pyo-KSR1 and Flag-B-RAF have been
described [18, 19] and constructs encoding HA- H-RASG12V, Pyo-KSR2, or
Pyo-BKSR1 were generated by subcloning. Point mutations were intro-
duced by site directed mutagenesis and confirmed by DNA sequencing.
Stable cell lines were generated by retroviral infection of KSR2/2 immortal-
ized MEFs, which are null for both KSR1 and KSR2 [8].
Cell Lysis, Coimmunoprecipitation Assays, Immune Complex
Kinase Assays
Cells were lysed in 1% Nonident P-40 buffer (20 mM Tris [pH 8.0], 137 mM
NaCl, 10% glycerol, 1% Nonident P40, 0.15 unit/mL aprotinin, 1 mM phe-
nylmethylsulfonyl fluoride [PMSF], 20 mM leupeptin, and 0.5 mM sodium
vanadate) and lysates were clarified by centrifugation. Protein concentra-
tions were determined and equivalent amounts of protein lysate were
incubated with the appropriate antibody and Protein G Sepharose beads
for 3 hr at 4C. Immune complexes were washed and analyzed either by
immunoblotting or in immune complex kinase assays as described in Ritt
et al. [19].
Cell Fractionation
Cell fractionation of KSR2/2 or WT-KSR1 MEFs was performed as
described previously [20]. The purity of the membrane and cytoplasmic
fractions were monitored by the presence of tubulin (cytoplasmic) and
H-RAS (membrane).
Figure 4. Effects of KSR1 on Inhibitor-Induced ERK
Cascade Activation
(A) KSR2/2 and WT-KSR1 MEFs were treated with
L779450 (10 mM for 1 hr). The catalytic activity of endog-
enous B-RAF and C-RAF proteins was measured in
immune-complex kinase assays using kinase-inactive
MEK as a substrate. Lysates were analyzed for pERK
and tubulin (loading control) levels. Bars represent the
mean 6 standard deviation of three independent exper-
iments.
(B) A549, HMCB, and A375 cells expressing either the
pLKO.1 vector or pLKO.1-KSR1 shRNA were treated as
indicated for 1hr. Lysates were analyzed for pERK and
tubulin levels. Depletion of KSR1 is also shown.
(C) Inhibitor-induced RAF dimerization occurs at the
plasma membrane and is RAS-dependent (left). Inhib-
itor-induced KSR1/B-RAF complexes can form in the
cytosol, thus inhibiting the formation of C-RAF/B-RAF
dimers at the membrane (right).
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Supplemental Information includes four figures, one table, and Supple-
mental Experimental Procedures and can be found with this article online
at doi:10.1016/j.cub.2011.02.033.
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